Pacira Biosciences Inc. (PCRX)

38.27
1.10 2.80
NASDAQ : Health Technology
Prev Close 39.38
Open 39.63
Day Low/High 38.23 / 39.74
52 Wk Low/High 35.07 / 55.00
Volume 225.38K
Avg Volume 499.40K
Exchange NASDAQ
Shares Outstanding 41.63M
Market Cap 1.58B
P/E Ratio 199.74
Div & Yield N.A. (N.A)
Pacira Pharmaceuticals (PCRX) Stock Slumps Following Q4 Results

Pacira Pharmaceuticals (PCRX) Stock Slumps Following Q4 Results

Pacira Pharmaceuticals (PCRX) stock is falling on Thursday after the company reported its 2015 fourth quarter results before today’s opening bell.

Trade-Ideas: Pacira Pharmaceuticals (PCRX) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Pacira Pharmaceuticals (PCRX) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a weak on high relative volume candidate

PCRX: Insiders vs. Shorts

PCRX: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 12/31/2015 settlement date, and Pacira Pharmaceuticals Inc. is one of the most shorted stocks of the Russell 3000, based on 10.02 "days to cover" versus the median component at 5.74.

Insider Trading Alert - HIL, PCRX And LMAT Traded By Insiders

Insider Trading Alert - HIL, PCRX And LMAT Traded By Insiders

Stocks with insider trader activity include HIL, PCRX and LMAT

Trade-Ideas: Pacira Pharmaceuticals (PCRX) Is Today's "Barbarian At The Gate" Stock

Trade-Ideas: Pacira Pharmaceuticals (PCRX) Is Today's "Barbarian At The Gate" Stock

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Pacira Pharmaceuticals (PCRX) Stock Surges After Regulators Resolve Free Speech Dispute

Pacira Pharmaceuticals (PCRX) Stock Surges After Regulators Resolve Free Speech Dispute

Pacira Pharmaceuticals (PCRX) stock is gaining in early afternoon trading on Tuesday after the company resolved a free speech dispute with the FDA regarding its drug labels.

Strong On High Volume: Pacira Pharmaceuticals (PCRX)

Strong On High Volume: Pacira Pharmaceuticals (PCRX)

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a strong on high relative volume candidate

New Survey Sheds Light On Prescription Drug Use Among Women After Surgery In The United States

New Survey Sheds Light On Prescription Drug Use Among Women After Surgery In The United States

Pacira and HealthyWomen Launch 'Voice Your Choice' Campaign Urging Patients to Know and Discuss Their Pain Control Options Before Surgery

New Study Finds Decreased Opioid Use, Hospital Stay And Readmission Rates With EXPAREL Following Knee Replacement Surgery

New Study Finds Decreased Opioid Use, Hospital Stay And Readmission Rates With EXPAREL Following Knee Replacement Surgery

Data Presented at the Annual Meeting of the American Association of Hip and Knee Surgeons

Today's Dead Cat Bounce Stock: Pacira Pharmaceuticals (PCRX)

Today's Dead Cat Bounce Stock: Pacira Pharmaceuticals (PCRX)

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a "dead cat bounce" (down big yesterday but up big today) candidate

5 Lesser-Known Stocks Goldman Sachs Recommends You Trust

5 Lesser-Known Stocks Goldman Sachs Recommends You Trust

These companies aren't household names, but they're on track for market-beating performance.

Goldman Sachs Picks 8 Small-Cap Stocks Poised to Double Earnings in 3 Years

Goldman Sachs Picks 8 Small-Cap Stocks Poised to Double Earnings in 3 Years

The recent pullback has created opportunity to buy small-cap stocks, particularly those with strong growth prospects over the next few years. Here's Goldman's picks.

Pacira Pharmaceuticals (PCRX) Strong On High Relative Volume Today

Pacira Pharmaceuticals (PCRX) Strong On High Relative Volume Today

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a strong on high relative volume candidate

Pacira Pharmaceuticals is Now Oversold

Pacira Pharmaceuticals is Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Pacira Pharmaceuticals (PCRX) Is Weak On High Volume Today

Pacira Pharmaceuticals (PCRX) Is Weak On High Volume Today

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a weak on high relative volume candidate

Insider Trading Alert - MRD, RNR And PCRX Traded By Insiders

Insider Trading Alert - MRD, RNR And PCRX Traded By Insiders

Stocks with insider trader activity include MRD, RNR and PCRX

Pacira Pharmaceuticals Seeks Court Injunction To Defend Its Rights To Share Information About EXPAREL® Consistent With Its FDA-Approved Indication

Pacira Pharmaceuticals Seeks Court Injunction To Defend Its Rights To Share Information About EXPAREL® Consistent With Its FDA-Approved Indication

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today filed a lawsuit against the U.

Pacira Pharmaceuticals (PCRX) Weak On High Volume

Pacira Pharmaceuticals (PCRX) Weak On High Volume

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a weak on high relative volume candidate

Pacira Pharmaceuticals Appoints James B. Jones, MD, PharmD, As Senior Vice President And Chief Medical Officer

Pacira Pharmaceuticals Appoints James B. Jones, MD, PharmD, As Senior Vice President And Chief Medical Officer

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the appointment of James B.

Bluebird, Pacira Pharmaceuticals Excite Life Science Investors

Bluebird, Pacira Pharmaceuticals Excite Life Science Investors

These stocks have had a really good run, says Wedbush Securities, which is holding its annual health care investment conference in New York.

TheStreet Quant Rating: C (Hold)